FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2566964764> ?p ?o ?g. }

• W2566964764 abstract "Abstract Background: Preclinical work from our group and others has demonstrated that the combination of a farnesyl transferase inhibitor (FTI) and the proteasome inhibitor bortezomib results in enhanced plasma cell apoptosis and is associated with AKT activation (David, Blood 2005). More recently, further preclinical data suggests that the mechanism responsible for this profound synergy is due to inhibition of HDAC6 with a resultant inhibition of both the proteasome and aggresome pathway (David ASH 2007). Based upon these observations, with the MMRC we initiated a phase I trial combining the FTI tipifarnib with bortezomib to clinically evaluate the efficacy of this combination. Methods: Patients with relapsed or refractory myeloma were treated with bortezomib at 1.0 mg/m2 given on days 1,4,8, and 11 in conjunction with escalating doses of tipifarnib (100–400mg/BID) given on days 2–15 every 21 days. Dose escalation was accomplished using an adaptive phase I design (Escalation With Overdose Control (EWOC)). Eligibility criteria included a serum creatinine of <2.5, normal liver function, ANC>500, and platelets >25. If dose escalation is able to proceed to 400mg of tipifarnib with 1.0 mg/m2, the tipifarnib dose escalation will restart with bortezomib given at 1.3 mg/m2. Results: Sixteen patients have been enrolled to date into respective tipifarnib dose levels 100 mg(n=6),200mg (n=5) and 300mg (n=5). Median age for the enrolled patients is 59 (range 43–76) and median time from myeloma diagnosis was 4.7 years. 15/16 patients had received prior high dose therapy. The average number of prior therapies was 4.5, and of the16 patients, 8 were refractory to prior bortezomib (relapsed on therapy or within 6 months) 4 were bortezomib naïve, and 4 were previously exposed to bortezomib but not known to be refractory. Among these patients with advanced myeloma and refractory disease, stabilization of disease or better was seen among 7/16 patients with 2 of the 7 achieving an MR. Of note, among the patients achieving clinical benefit, 1 patient had a stable M-protein, but experienced an 80% reduction in circulating plasma cells while on therapy, and another has had a 75% reduction in the free light chain assay. The most common drug related side effects were was Gr2 diarrhea (23.5%). Hematologic toxicities were difficult to ascertain as patients had advanced myeloma and many were entered onto study with platelet counts between 25 and 50. Additional grade 3 toxicities included renal insufficiency (related to progression), pneumonia and altered mental status which were all considered unrelated to study drug, but were associated with progression of disease. There were no Grade 3 –5 drug related toxicities. There were no cardiac events or DVT, and 1 patient experienced grade 2 peripheral neuropathy who did not have pre existing PN at baseline. Conclusions: The combination of bortezomib and tipifarnib is supported by preclinical rationale and has produced stable disease or better among a group of patients with refractory and advanced myeloma. To date the optimal dose of both tipifarnib and bortezomib have yet to be defined, and additional patients will be enrolled to define the MTD for tipifarnib with 1.0mg/m2 of bortezomib, followed by escalation of tipifarnib with 1.3mg/m2 of bortezomib. Correlative studies evaluating the effect of the combination on HDAC6 and plasma cell apoptosis will be presented." @default.
• W2566964764 created "2017-01-06" @default.
• W2566964764 creator A5003805183 @default.
• W2566964764 creator A5022075244 @default.
• W2566964764 creator A5023276777 @default.
• W2566964764 creator A5033267787 @default.
• W2566964764 creator A5035985145 @default.
• W2566964764 creator A5043490010 @default.
• W2566964764 creator A5046747674 @default.
• W2566964764 creator A5047438496 @default.
• W2566964764 creator A5070657256 @default.
• W2566964764 creator A5075570696 @default.
• W2566964764 creator A5079671419 @default.
• W2566964764 creator A5082712392 @default.
• W2566964764 creator A5085999045 @default.
• W2566964764 date "2008-11-16" @default.
• W2566964764 modified "2023-09-30" @default.
• W2566964764 title "A Phase I MMRC Clinical Trial Testing the Combination of Bortezomib and Tipifarnib in Relapsed/Refractory Multiple Myeloma" @default.
• W2566964764 doi "https://doi.org/10.1182/blood.v112.11.3706.3706" @default.
• W2566964764 hasPublicationYear "2008" @default.
• W2566964764 type Work @default.
• W2566964764 sameAs 2566964764 @default.
• W2566964764 citedByCount "6" @default.
• W2566964764 crossrefType "journal-article" @default.
• W2566964764 hasAuthorship W2566964764A5003805183 @default.
• W2566964764 hasAuthorship W2566964764A5022075244 @default.
• W2566964764 hasAuthorship W2566964764A5023276777 @default.
• W2566964764 hasAuthorship W2566964764A5033267787 @default.
• W2566964764 hasAuthorship W2566964764A5035985145 @default.
• W2566964764 hasAuthorship W2566964764A5043490010 @default.
• W2566964764 hasAuthorship W2566964764A5046747674 @default.
• W2566964764 hasAuthorship W2566964764A5047438496 @default.
• W2566964764 hasAuthorship W2566964764A5070657256 @default.
• W2566964764 hasAuthorship W2566964764A5075570696 @default.
• W2566964764 hasAuthorship W2566964764A5079671419 @default.
• W2566964764 hasAuthorship W2566964764A5082712392 @default.
• W2566964764 hasAuthorship W2566964764A5085999045 @default.
• W2566964764 hasConcept C126322002 @default.
• W2566964764 hasConcept C142424586 @default.
• W2566964764 hasConcept C143998085 @default.
• W2566964764 hasConcept C2776063141 @default.
• W2566964764 hasConcept C2776364478 @default.
• W2566964764 hasConcept C2777478702 @default.
• W2566964764 hasConcept C2778367456 @default.
• W2566964764 hasConcept C71924100 @default.
• W2566964764 hasConcept C86803240 @default.
• W2566964764 hasConcept C87355193 @default.
• W2566964764 hasConcept C98274493 @default.
• W2566964764 hasConceptScore W2566964764C126322002 @default.
• W2566964764 hasConceptScore W2566964764C142424586 @default.
• W2566964764 hasConceptScore W2566964764C143998085 @default.
• W2566964764 hasConceptScore W2566964764C2776063141 @default.
• W2566964764 hasConceptScore W2566964764C2776364478 @default.
• W2566964764 hasConceptScore W2566964764C2777478702 @default.
• W2566964764 hasConceptScore W2566964764C2778367456 @default.
• W2566964764 hasConceptScore W2566964764C71924100 @default.
• W2566964764 hasConceptScore W2566964764C86803240 @default.
• W2566964764 hasConceptScore W2566964764C87355193 @default.
• W2566964764 hasConceptScore W2566964764C98274493 @default.
• W2566964764 hasLocation W25669647641 @default.
• W2566964764 hasOpenAccess W2566964764 @default.
• W2566964764 hasPrimaryLocation W25669647641 @default.
• W2566964764 hasRelatedWork W2079167171 @default.
• W2566964764 hasRelatedWork W2099110265 @default.
• W2566964764 hasRelatedWork W2130696468 @default.
• W2566964764 hasRelatedWork W2143455585 @default.
• W2566964764 hasRelatedWork W2167498902 @default.
• W2566964764 hasRelatedWork W2171585059 @default.
• W2566964764 hasRelatedWork W2270022990 @default.
• W2566964764 hasRelatedWork W2497129282 @default.
• W2566964764 hasRelatedWork W2499238458 @default.
• W2566964764 hasRelatedWork W2547216979 @default.
• W2566964764 hasRelatedWork W2556678903 @default.
• W2566964764 hasRelatedWork W2557435100 @default.
• W2566964764 hasRelatedWork W2558178039 @default.
• W2566964764 hasRelatedWork W2571142173 @default.
• W2566964764 hasRelatedWork W2574084914 @default.
• W2566964764 hasRelatedWork W2580651706 @default.
• W2566964764 hasRelatedWork W2728443392 @default.
• W2566964764 hasRelatedWork W3108090032 @default.
• W2566964764 hasRelatedWork W3149596955 @default.
• W2566964764 hasRelatedWork W747621895 @default.
• W2566964764 isParatext "false" @default.
• W2566964764 isRetracted "false" @default.
• W2566964764 magId "2566964764" @default.
• W2566964764 workType "article" @default.